{"gene":"TXNIP","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2003,"finding":"VDUP1/TXNIP interacts with promyelocytic leukemia zinc-finger (PLZF), Fanconi anemia zinc-finger (FAZF), and histone deacetylase 1 (HDAC1), forming a transcriptional repressor complex that suppresses IL-3 receptor and cyclin A2 promoter activity, causing G0/G1 cell-cycle arrest.","method":"Co-immunoprecipitation, transfection/overexpression, reporter assays, cell-cycle analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — co-IP and reporter assays from single lab, multiple orthogonal methods confirming transcriptional repressor complex","pmids":["12821938"],"is_preprint":false},{"year":2005,"finding":"VDUP1/TXNIP interacts with JAB1 (CSN5) and blocks JAB1-mediated nuclear-to-cytoplasm translocation of p27(kip1), thereby stabilizing p27 and inhibiting cell proliferation. VDUP1-/- fibroblasts show reduced p27 and increased proliferation.","method":"Co-immunoprecipitation, VDUP1-/- fibroblast analysis, subcellular fractionation, cell proliferation assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal co-IP plus KO model with defined molecular phenotype, single lab","pmids":["15930262"],"is_preprint":false},{"year":2005,"finding":"VDUP1/TXNIP is required for NK cell development in vivo; VDUP1-/- mice show profound reduction in NK cell numbers and decreased NK activity, with reduced CD122 expression demonstrating that VDUP1 is required for CD122 expression and NK maturation.","method":"VDUP1-/- mouse model, flow cytometry, NK cytotoxicity assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with defined cellular phenotype, flow cytometry, multiple readouts in one study","pmids":["15723808"],"is_preprint":false},{"year":2006,"finding":"TXNIP is a glucocorticoid receptor primary response gene; a functional glucocorticoid response element (GRE) in the TXNIP promoter mediates dexamethasone-induced transcription, and TXNIP expression is sufficient to induce apoptosis in T lymphoma cells; RNAi knockdown of TXNIP inhibits glucocorticoid-induced apoptosis.","method":"Promoter deletion/mutation analysis, reporter assays, GFP-TXNIP overexpression, siRNA knockdown, Northern blot","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — promoter mutagenesis with reporter assays plus loss- and gain-of-function in the same study, single lab","pmids":["16301999"],"is_preprint":false},{"year":2006,"finding":"Txnip deficiency in mice (HcB-19 strain with spontaneous Txnip mutation) causes spontaneous hepatocellular carcinoma (~40% incidence), with increased alpha-fetoprotein and p53, demonstrating Txnip is a tumor suppressor gene required in vivo to prevent HCC.","method":"Recombinant inbred congenic mouse model, cosegregation analysis, histology, BrdU labeling, microarray","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic cosegregation in congenic strain, histological confirmation, multiple molecular markers","pmids":["16607285"],"is_preprint":false},{"year":2007,"finding":"VDUP1/TXNIP associates with the beta-domain of pVHL, enhances the pVHL–HIF1α interaction, and promotes CRM1-dependent nuclear export and degradation of HIF1α, suppressing cell invasiveness and tumor metastasis. Blocking VDUP1 nuclear export with leptomycin B or NES mutation inhibits HIF1α destabilization.","method":"Co-immunoprecipitation, nuclear export inhibition (leptomycin B), NES mutation, invasion/metastasis assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — co-IP with VHL, pharmacological and genetic blockade of export, single lab, multiple orthogonal approaches","pmids":["18062927"],"is_preprint":false},{"year":2016,"finding":"IL-1β down-regulates TXNIP transcription via inhibition of carbohydrate response element binding protein (ChREBP) activity, while IFNγ increases TXNIP post-transcriptionally by inducing ER stress, activating IRE1α, and suppressing miR-17, a microRNA that targets TXNIP mRNA. miR-17 knockdown mimics IFNγ effects on TXNIP; miR-17 overexpression blunts IFNγ-induced TXNIP elevation.","method":"TXNIP promoter analysis, chromatin immunoprecipitation (ChIP), miR-17 overexpression/knockdown, IRE1α inhibition, primary islet studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP, promoter analysis, miRNA gain/loss-of-function, validated in both INS-1 cells and primary islets in single study","pmids":["26858253"],"is_preprint":false},{"year":2018,"finding":"Hyaluronan/ECM remodeling triggers receptor tyrosine kinase-mediated induction of the mRNA decay factor ZFP36, which targets TXNIP transcripts for degradation; acute TXNIP decline enriches GLUT1 at the plasma membrane because TXNIP normally promotes internalization (endocytosis) of GLUT1, thereby increasing glycolysis and cell migration.","method":"Unbiased glycolytic driver screen, hyaluronidase treatment of cells and xenografts, ZFP36 induction assays, GLUT1 surface trafficking analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (mRNA decay assay, surface GLUT1 quantification, xenograft validation), replicated across cell types and in vivo","pmids":["30197082"],"is_preprint":false},{"year":2019,"finding":"TXNIP directly interacts with and positively regulates phosphorylated AMPK (p-PRKAA), leading to inactivation of mTORC1 and nuclear translocation of TFEB, which promotes autophagy and fatty acid oxidation. Txnip-KO mice show impaired autophagy and fatty acid oxidation; rapamycin rescues this phenotype.","method":"Co-immunoprecipitation (TXNIP–AMPK), txnip-KO mice, rapamycin rescue, Atg7 silencing epistasis, nuclear TFEB localization","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus KO mouse model with mechanistic rescue, single lab","pmids":["33190588"],"is_preprint":false},{"year":2019,"finding":"ERK MAPK phosphorylates TXNIP at Thr349 within a PXTP motif in its C-terminal α-arrestin domain, triggering ubiquitination and proteasomal degradation of TXNIP, thereby releasing thioredoxin oxidoreductase activity; ERK inhibition augments intracellular ROS and S-nitrosothiols.","method":"ERK inhibitor pharmacology, site-directed mutagenesis of Thr349, ubiquitination assay, proteasome inhibition, ROS/S-nitrosothiol measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of phospho-site plus ubiquitination assay plus functional ROS readout, single lab with multiple orthogonal methods","pmids":["31320475"],"is_preprint":false},{"year":2019,"finding":"TXNIP interacts with and shifts intracellularly from the nucleus to mitochondria under oxidative stress (MSU crystals); TXNIP directly binds NLRP3 under these conditions to activate the NLRP3 inflammasome and NF-κB signaling; antioxidants and TXNIP siRNA block this interaction and suppress inflammasome activation.","method":"Western blot, co-immunoprecipitation, TXNIP siRNA, subcellular fractionation, immunofluorescence localization","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP for TXNIP–NLRP3 interaction plus siRNA knockdown with functional inflammasome readout, single lab","pmids":["30833078"],"is_preprint":false},{"year":2019,"finding":"TXNIP nucleoprotein complex: TXNIP forms redox-sensitive high molecular weight complexes (~1000–1300 kDa) in the nuclear fraction, partially dissolved by DTT; binding partners identified by tandem affinity purification and proteomics include HSP90, HSP70, and Prp31.","method":"Tandem affinity purification, proteomics (MS), native PAGE, DTT disruption, RNAse treatment","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics + native PAGE + chemical disruption evidence for redox-sensitive complex, single lab","pmids":["31669268"],"is_preprint":false},{"year":2021,"finding":"TXNIP interacts with GLUT1 in a 1:1 ratio, and this interaction requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2); TXNIP acts as an adaptor for GLUT1 in clathrin-mediated endocytosis to reduce glucose uptake, using its C-terminal arrestin domain and di-leucine endocytic motif.","method":"GLUT1 lipid nanodiscs, isothermal titration calorimetry (ITC), single-particle electron microscopy, PIP2 requirement tested","journal":"Biochimica et biophysica acta. Biomembranes","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with nanodiscs, ITC (quantitative binding), electron microscopy, identification of lipid cofactor requirement in single study","pmids":["34478732"],"is_preprint":false},{"year":2021,"finding":"Txnip C247S mutation abolishes disulfide bond formation with thioredoxin; cardiomyocyte-specific C247S knock-in mice have smaller infarct sizes after myocardial infarction with reduced ROS, demonstrating that Txnip's inhibition of thioredoxin via C247 disulfide is required for its pro-oxidative, cytotoxic effects in the heart.","method":"Site-directed mutagenesis, conditional knock-in mouse model, ROS measurement, infarct size quantification, RNA-seq","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis of catalytic cysteine in vivo with conditional knock-in model and multiple functional readouts","pmids":["33652022"],"is_preprint":false},{"year":2021,"finding":"Txnip directly binds STAT3 (confirmed by co-immunoprecipitation) and activates the STAT3 signaling pathway in renal tubular epithelial cells, thereby promoting a profibrotic response and accelerating renal aging; STAT3 inhibitor blocks TXNIP-mediated fibrosis.","method":"Co-immunoprecipitation, TXNIP overexpression/siRNA in tubular cells, TXNIP-KO mice, STAT3 inhibitor rescue","journal":"Mechanisms of ageing and development","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single co-IP plus KO mouse model and pharmacological rescue, single lab","pmids":["33781783"],"is_preprint":false},{"year":2021,"finding":"Corticosterone (chronic stress hormone) increases TXNIP protein and TXNIP–NLRP3 binding in microglia; CRISPR/Cas9 knockout of Txnip inhibits corticosterone-induced caspase-1 activity and IL-1β release, placing Txnip upstream of the NLRP3 inflammasome in corticosterone-induced neuroinflammation.","method":"Co-immunoprecipitation (TXNIP–NLRP3), CRISPR/Cas9 Txnip knockout, caspase-1 activity assay, ELISA for IL-1β","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — CRISPR KO with defined functional readout and co-IP, single lab","pmids":["31586460"],"is_preprint":false},{"year":2022,"finding":"SIRT6 transcriptionally suppresses TXNIP by deacetylating H3K9ac and H3K56ac at the TXNIP locus (confirmed by ChIP), reducing TXNIP expression and thereby inhibiting microglial activation and promoting angiogenesis in cerebral ischemia.","method":"ChIP assay for SIRT6 occupancy and H3 deacetylation, SIRT6 overexpression, energy restriction diet model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with histone mark validation plus SIRT6 overexpression in cell and in vivo models, single lab","pmids":["35562171"],"is_preprint":false},{"year":2022,"finding":"PIAS3 interacts with SMAD2/3 to activate TGF-β signaling, increasing TXNIP expression; TXNIP is required downstream of PIAS3 for ferroptotic cell death in hepatocellular carcinoma cells. TXNIP knockdown reduces PIAS3-overexpression-induced ferroptosis; forced TXNIP re-expression restores ferroptosis sensitivity.","method":"TMT-based proteomics, RNA-seq, co-immunoprecipitation (PIAS3–SMAD2/3), TXNIP knockdown/overexpression, ferroptosis assays","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — co-IP, epistatic rescue experiments, two orthogonal methods, single lab","pmids":["37689128"],"is_preprint":false},{"year":2022,"finding":"SIRT1 acts as an upstream negative regulator of TXNIP/NLRP3 inflammasome activity in lens epithelial cells under high glucose; si-SIRT1 and LV-SIRT1 had inverse effects on NLRP3 inflammasome activation, and TXNIP knockdown inhibited NLRP3-induced IL-1β secretion.","method":"siRNA knockdown, lentiviral overexpression, NLRP3/TXNIP siRNA, Western blot, ROS measurement in HLECs and ex vivo rat lenses","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal gain/loss-of-function for SIRT1 and TXNIP, two cell models, single lab","pmids":["36881408"],"is_preprint":false},{"year":2022,"finding":"TXNIP suppresses the osteochondrogenic transition of vascular smooth muscle cells (VSMCs) by inhibiting BMP signaling; smooth-muscle-specific Txnip knockout (Tagln-Cre; Txnip-flox) recapitulates increased atherosclerotic calcification and expanded osteochondrogenic clusters; BMP inhibitor K02288 abrogates the effect of TXNIP suppression on osteodifferentiation.","method":"Conditional VSMC-specific KO mice, single-cell RNA-seq, BMP inhibitor rescue, primary VSMC culture with TXNIP suppression","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with scRNA-seq pathway analysis, pharmacological rescue, and human data reanalysis","pmids":["36448450"],"is_preprint":false},{"year":2023,"finding":"NEDD4L is the E3 ubiquitin ligase responsible for TXNIP ubiquitination and proteasomal degradation in hepatocytes; decreased NEDD4L in NASH leads to impaired TXNIP ubiquitination and accumulation of TXNIP protein. TXNIP C-terminus associates with the α-helix domain N-terminus of CHOP, decreasing CHOP ubiquitination and stabilizing CHOP protein to drive ER stress-mediated apoptosis.","method":"Four NASH mouse models, E3 ligase screen, co-immunoprecipitation (TXNIP–CHOP), ubiquitination assay, adenovirus-mediated shRNA KD, gain/loss-of-function studies","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reconstitution of ubiquitination pathway, co-IP of TXNIP–CHOP, multiple NASH models, mechanistic rescue, single lab with many orthogonal methods","pmids":["37153733"],"is_preprint":false},{"year":2023,"finding":"TXNIP shuttles between thioredoxin (TRX) and class I GLUTs (GLUT1–4) depending on intracellular ROS levels; elevated ROS shifts TXNIP from TRX to GLUTs via the C-terminal arrestin (C-ARR) domain; TXNIP then promotes lysosomal degradation of GLUTs through its di-leucine endocytic motif, reducing glucose uptake and suppressing glycolysis, hexosamine biosynthesis, and the pentose phosphate pathway.","method":"Co-immunoprecipitation, domain-swap/deletion mutants, ROS manipulation, GLUT surface expression, lysosomal inhibition, metabolic flux assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple co-IP experiments with mutants identifying C-ARR domain, lysosomal pathway confirmed, metabolic readouts, single lab","pmids":["38329960"],"is_preprint":false},{"year":2023,"finding":"USP5 deubiquitylase interacts with TXNIP (confirmed by co-immunoprecipitation) and stabilizes TXNIP by removing its ubiquitin modifications; USP5 knockdown reduces TXNIP levels, increases cell viability, and decreases inflammasome/apoptotic signaling in LPS-treated hepatocytes.","method":"Overexpression screen for deubiquitinase stabilizing TXNIP, co-immunoprecipitation, siRNA knockdown, ubiquitination assay","journal":"Hepatology communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP screen plus KD rescue, single lab, identifies specific DUB","pmids":["37534934"],"is_preprint":false},{"year":2023,"finding":"SIRT1 deacetylates H3K9 at the TXNIP promoter (demonstrated by ChIP-qPCR) to repress TXNIP transcription; exenatide (exendin-4) upregulates SIRT1, which reduces TXNIP H3K9ac and decreases XBP1s recruitment to the TXNIP promoter, lowering TXNIP expression and protecting against diabetic kidney disease.","method":"ChIP-qPCR, whole-body and kidney-specific Sirt1 KO mice, exendin-4 treatment, XBP1s recruitment analysis","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR for histone modification plus conditional KO mice, single lab","pmids":["37742607"],"is_preprint":false},{"year":2019,"finding":"Txnip BioID proximity labeling identified 31 interacting proteins; many interactions were disrupted by C247S mutation, demonstrating redox-dependent binding; hyperglycemia dynamically alters Txnip interactions, revealing that Txnip's pleiotropic functions are mediated through distinct, condition-specific protein complexes.","method":"BioID proximity labeling fused to Txnip in HEK293 cells, C247S mutant comparison, mass spectrometry","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity labeling proteomics with reactive cysteine mutant to distinguish redox-dependent interactions, single lab","pmids":["27437069"],"is_preprint":false},{"year":2018,"finding":"Oncogenic Ras suppresses TXNIP protein synthesis by reducing ribosome transit rate along the TXNIP mRNA coding region (translational elongation); the N-terminal nascent TXNIP polypeptide is the target for Ras-dependent translational repression, independent of codon usage, mRNA secondary structure, or miRNAs.","method":"Ribosome profiling-based translational elongation assay, codon-randomized/optimized TXNIP mRNA variants, N-terminal truncation mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ribosome transit assay plus mutagenesis of mRNA sequence variants to dissect mechanism, single lab with multiple orthogonal approaches","pmids":["30037981"],"is_preprint":false},{"year":2021,"finding":"ChREBP and FoxO1 both up-regulate TxNIP expression in hepatocytes; genetic studies in mice with liver-specific deletion of ChREBP or FoxO1 show that both transcription factors are required for full TxNIP induction in response to glucose and fasting, respectively.","method":"Genetically modified mice (ChREBP and FoxO1 liver-specific models), gene expression analysis, db/db hyperglycemia model","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent genetic mouse models identifying dual transcriptional regulators, single lab","pmids":["33748706"],"is_preprint":false},{"year":2020,"finding":"Glucose-6-phosphate (G6P) directly activates the transcription factor heterodimer MondoA/Mlx to upregulate TXNIP expression; EMSA and endogenous knockdown confirmed G6P (not glucose itself) as the activating metabolic intermediate. Mutational analysis of MondoA identified GKL139-141 residues as mediating G6P binding.","method":"EMSA (gel mobility shift), endogenous knockdown of MondoA, molecular docking, mutational analysis of MondoA binding residues","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus mutagenesis to identify G6P binding residues in MondoA, single lab","pmids":["31993438"],"is_preprint":false},{"year":2023,"finding":"MondoA-induced TXNIP transcription is activated by lactic acid via SENP1-dependent deSUMOylation of MondoA; in CD8+ T cells, the MondoA–TXNIP axis impairs TCR/CD28 signaling-induced activation by reducing glucose uptake and glycolysis; in Treg cells, TXNIP promotes immunosuppressive function.","method":"MondoA-deficient T cell models, glucose uptake assays, TCR activation assays, tumor immunotherapy models with anti-PD-1 combination","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic MondoA deletion in two T cell subsets, mechanistic pathway identification via SENP1, validated in multiple cancer models with combination therapy","pmids":["40846790"],"is_preprint":false},{"year":2024,"finding":"TXNIP interacts with TAK1 (transforming growth factor β-activated kinase 1) in liver sinusoidal endothelial cells (LSECs) and suppresses the TAK1 pathway, thereby maintaining nitric oxide (NO) production; endothelial Txnip deletion leads to sinusoidal capillarization, reduced NO, increased pro-inflammatory cytokines, and aggravated alcohol-associated liver disease.","method":"Co-immunoprecipitation (TXNIP–TAK1), endothelial-specific Txnip KO mice, TXNIP overexpression in LSECs, TAK1 inhibitor rescue","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — co-IP identifying novel partner, cell-type-specific KO with pharmacological rescue, single lab","pmids":["38169654"],"is_preprint":false},{"year":2019,"finding":"Elevated TXNIP in RPE cells undergoes downregulation under oxidative stress; TXNIP knockdown induces autophagic flux causing nuclear localization of p53, enhanced AMPK phosphorylation, disruption of tight junctions (via Src kinase phosphorylation), and increased HIF-1α leading to VEGF secretion from RPE cells.","method":"TXNIP siRNA knockdown in RPE cells, autophagy flux assay, subcellular localization of p53, Src kinase activity measurement, VEGF ELISA, co-culture angiogenesis assay","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA knockdown with multiple downstream readouts in single lab identifying mechanistic cascade","pmids":["31615975"],"is_preprint":false},{"year":2023,"finding":"TXNIP loss in MDA-MB-231 TNBC cells increases global Myc genome occupancy, allowing Myc to invade promoters and enhancers of additional target genes, expanding the Myc-dependent transcriptome without increasing Myc protein levels or Myc's intrinsic transcriptional activity.","method":"TXNIP null (CRISPR KO) MDA-MB-231 cells, ChIP-seq for Myc genome-wide occupancy, RNA-seq","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — genome-wide ChIP-seq plus RNA-seq in CRISPR KO cells demonstrating mechanistic link between TXNIP loss and Myc occupancy, single lab","pmids":["36930677"],"is_preprint":false}],"current_model":"TXNIP is a multifunctional α-arrestin scaffold protein that inhibits thioredoxin antioxidant activity via a C247 disulfide bond, promotes lysosomal degradation of GLUT1-4 through its C-ARR domain and di-leucine endocytic motif (requiring PI(4,5)P2) to limit glucose uptake, activates the NLRP3 inflammasome by directly binding NLRP3 under oxidative stress, suppresses tumor progression by stabilizing p27 (via JAB1 inhibition), facilitating HIF1α nuclear export and degradation (via pVHL), and broadly restraining Myc genomic occupancy; its expression is transcriptionally controlled by glucose-6-phosphate/MondoA-Mlx, ChREBP, FoxO1, glucocorticoid receptor, and SIRT6/SIRT1-dependent histone deacetylation, and its protein stability is regulated by ERK-phosphorylation at Thr349 driving NEDD4L/ubiquitin-proteasomal degradation or USP5-mediated stabilization."},"narrative":{"mechanistic_narrative":"TXNIP is a redox-responsive α-arrestin scaffold that couples cellular oxidative and metabolic state to glucose handling, antioxidant capacity, inflammation, and cell-fate decisions [PMID:38329960, PMID:27437069]. Its defining redox switch is the C247 disulfide bond with thioredoxin: this cysteine-dependent inhibition of thioredoxin oxidoreductase drives pro-oxidative, cytotoxic outcomes, and a cardiomyocyte C247S knock-in limits infarct size with reduced ROS [PMID:33652022]. Rising ROS releases TXNIP from thioredoxin and redirects it through its C-terminal arrestin (C-ARR) domain and di-leucine endocytic motif onto class I glucose transporters GLUT1–4, which TXNIP internalizes (binding GLUT1 in a 1:1, PI(4,5)P2-dependent manner) and routes to lysosomal degradation, thereby restraining glucose uptake, glycolysis, the hexosamine and pentose phosphate pathways [PMID:34478732, PMID:38329960]. TXNIP additionally acts as a tumor suppressor: it is required in vivo to prevent hepatocellular carcinoma, stabilizes p27(kip1) by blocking JAB1/CSN5-mediated nuclear export, promotes pVHL/CRM1-dependent nuclear export and degradation of HIF1α to suppress invasion, and restrains genome-wide Myc occupancy [PMID:16607285, PMID:15930262, PMID:18062927, PMID:36930677]. Under oxidative stress TXNIP relocates and directly binds NLRP3 to activate the inflammasome and downstream caspase-1/IL-1β release, linking it to gout, glucocorticoid/corticosterone, and high-glucose inflammatory responses [PMID:30833078, PMID:31586460, PMID:36881408]. It also engages signaling and stability partners including AMPK (driving mTORC1 inactivation, TFEB nuclear translocation, autophagy and fatty acid oxidation), STAT3, TAK1, and CHOP, the last stabilized by TXNIP to promote ER-stress apoptosis [PMID:33190588, PMID:33781783, PMID:38169654, PMID:37153733]. TXNIP abundance is set by extensive transcriptional control via glucose-6-phosphate/MondoA-Mlx, ChREBP, FoxO1, the glucocorticoid receptor, and SIRT6/SIRT1-dependent histone deacetylation, and by post-translational stability control through ERK phosphorylation at Thr349, NEDD4L-mediated ubiquitination, and USP5-mediated deubiquitination [PMID:31993438, PMID:33748706, PMID:16301999, PMID:35562171, PMID:37742607, PMID:31320475, PMID:37153733, PMID:37534934].","teleology":[{"year":2003,"claim":"Established an early function for TXNIP as a transcriptional co-repressor controlling cell-cycle exit, the first hint that it acts as a scaffold within nuclear complexes.","evidence":"Co-IP, reporter and cell-cycle assays linking TXNIP to PLZF/FAZF/HDAC1 repression of IL-3 receptor and cyclin A2","pmids":["12821938"],"confidence":"Medium","gaps":["Direct DNA binding by TXNIP not demonstrated","Physiological relevance outside overexpression unclear"]},{"year":2005,"claim":"Defined how TXNIP restrains proliferation, by stabilizing the CDK inhibitor p27 through inhibition of JAB1-driven nuclear export, and showed it is required for NK cell maturation in vivo.","evidence":"Reciprocal co-IP and VDUP1-/- fibroblasts (p27); VDUP1-/- mice and flow cytometry (NK/CD122)","pmids":["15930262","15723808"],"confidence":"High","gaps":["Whether p27 and NK phenotypes share a single molecular mechanism unresolved","Structural basis of JAB1 inhibition not defined"]},{"year":2006,"claim":"Demonstrated that TXNIP is a glucocorticoid-receptor primary response gene mediating apoptosis and a bona fide tumor suppressor required to prevent hepatocellular carcinoma in vivo.","evidence":"GRE promoter mutagenesis with gain/loss-of-function (Oncogene 2006); HcB-19 Txnip-mutant congenic mice with HCC cosegregation","pmids":["16301999","16607285"],"confidence":"High","gaps":["Molecular effectors of TXNIP-driven apoptosis not defined in 2006","Link between tumor suppression and redox/metabolic functions not yet made"]},{"year":2007,"claim":"Connected TXNIP to hypoxia signaling and metastasis suppression by showing it enhances pVHL–HIF1α interaction and promotes CRM1-dependent nuclear export/degradation of HIF1α.","evidence":"Co-IP with pVHL, leptomycin B and NES-mutant export blockade, invasion/metastasis assays","pmids":["18062927"],"confidence":"Medium","gaps":["Direct vs scaffolded contribution to HIF1α degradation not separated","In vivo metastasis dependence on this axis not genetically tested"]},{"year":2016,"claim":"Resolved how inflammatory cytokines tune TXNIP, with IL-1β repressing ChREBP-driven transcription and IFNγ raising TXNIP post-transcriptionally via IRE1α/miR-17.","evidence":"ChIP, promoter analysis, miR-17 gain/loss-of-function and IRE1α inhibition in INS-1 cells and primary islets","pmids":["26858253"],"confidence":"High","gaps":["Integration of opposing cytokine inputs on net TXNIP level in vivo unclear","Whether miR-17 directly binds TXNIP 3'UTR shown only indirectly"]},{"year":2018,"claim":"Established TXNIP as a direct adaptor for GLUT1 internalization and identified two distinct upstream controls — ZFP36-mediated mRNA decay and Ras-mediated translational elongation repression — that lower TXNIP to boost glycolysis.","evidence":"Glycolytic driver screen, ZFP36 mRNA-decay and surface-GLUT1 assays, xenografts (Cell 2018); ribosome transit assays and mRNA/N-terminal mutants (MCB 2018)","pmids":["30197082","30037981"],"confidence":"High","gaps":["Whether elongation control and decay act on the same TXNIP pool unknown","Endocytic machinery for GLUT1 internalization not yet structurally defined"]},{"year":2019,"claim":"Mapped multiple regulatory and effector arms: ERK-Thr349 phosphorylation triggering proteasomal degradation, direct NLRP3 binding to activate the inflammasome, AMPK–mTORC1–TFEB control of autophagy, and a redox-dependent BioID interactome.","evidence":"Thr349 mutagenesis/ubiquitination/ROS assays; TXNIP–NLRP3 co-IP and siRNA; TXNIP–AMPK co-IP with Txnip-KO and rapamycin rescue; BioID with C247S comparison","pmids":["31320475","30833078","33190588","27437069","31615975"],"confidence":"High","gaps":["Whether single TXNIP molecule scaffolds multiple effectors or pools partition by condition unresolved","Direct NLRP3 binding interface not defined"]},{"year":2021,"claim":"Provided biophysical and genetic anchors for core mechanisms: reconstituted 1:1 PI(4,5)P2-dependent TXNIP–GLUT1 binding, and an in vivo C247S knock-in proving the thioredoxin disulfide drives pro-oxidative cardiac injury; expanded the partner set to STAT3 and nuclear HMW redox complexes.","evidence":"GLUT1 nanodiscs, ITC and EM (BBA Biomembranes); cardiac C247S knock-in with ROS/infarct readouts; STAT3 co-IP with KO/inhibitor; tandem-affinity proteomics (HSP90/HSP70/Prp31)","pmids":["34478732","33652022","33781783","31669268","33748706","31586460"],"confidence":"High","gaps":["Stoichiometry and composition of nuclear HMW complexes not fully defined","STAT3 and TAK1 binding interfaces not mapped"]},{"year":2022,"claim":"Extended transcriptional control via SIRT6 histone deacetylation and identified context-specific roles in vascular calcification (BMP suppression), ferroptosis (downstream of PIAS3/TGF-β), and inflammasome regulation by SIRT1.","evidence":"SIRT6 ChIP with H3K9/H3K56ac; VSMC-specific Txnip KO with scRNA-seq and BMP inhibitor rescue; PIAS3–SMAD2/3 co-IP with TXNIP epistasis; SIRT1 gain/loss in lens epithelium","pmids":["35562171","36448450","37689128","36881408"],"confidence":"High","gaps":["How TXNIP toggles between pro-survival and pro-death outputs not mechanistically unified","Direct molecular target through which TXNIP modulates BMP signaling unknown"]},{"year":2023,"claim":"Consolidated the ROS-gated TRX-to-GLUT shuttling model, defined the NEDD4L–USP5 ubiquitin/deubiquitin axis (and CHOP stabilization), added SIRT1/XBP1s promoter control, and revealed TXNIP restrains genome-wide Myc occupancy and shapes T-cell metabolism via MondoA.","evidence":"Domain-swap co-IP and metabolic flux (PLoS ONE); NEDD4L E3 screen and TXNIP–CHOP co-IP across NASH models; USP5 DUB screen; SIRT1 ChIP-qPCR/XBP1s; Myc ChIP-seq/RNA-seq in CRISPR-KO TNBC; MondoA-deletion T cells with SENP1 axis","pmids":["38329960","37153733","37534934","37742607","36930677","40846790"],"confidence":"High","gaps":["Mechanism by which TXNIP loss permits Myc promoter/enhancer invasion is unresolved","Whether GLUT-binding and Myc-restraining functions are linked unknown"]},{"year":2024,"claim":"Added an endothelial protective role in which TXNIP suppresses TAK1 to preserve nitric oxide and limit liver sinusoidal capillarization.","evidence":"TXNIP–TAK1 co-IP, endothelial-specific Txnip KO, overexpression and TAK1 inhibitor rescue in LSECs","pmids":["38169654"],"confidence":"Medium","gaps":["TAK1 binding interface and whether inhibition is direct vs scaffolded not defined","Single-lab co-IP without reciprocal structural validation"]},{"year":null,"claim":"A unifying structural and biochemical model explaining how one redox-sensing α-arrestin partitions among thioredoxin, GLUT transporters, NLRP3, p27/JAB1, HIF1α, and Myc-restraining functions across cell types remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of full-length TXNIP bound to its major partners","Rules governing condition-specific complex selection not established","Direct DNA/chromatin relationship underlying Myc restraint unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[12,21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[13,1,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,31]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[12,21]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,11,31]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[24,21]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[10]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[12,21]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[12,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,15,18,2]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[13,9,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[27,26,3,16,23]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[9,20,22]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[8]}],"complexes":["NLRP3 inflammasome","PLZF/FAZF/HDAC1 transcriptional repressor complex","pVHL-HIF1α complex"],"partners":["GLUT1","NLRP3","JAB1","VHL","AMPK","STAT3","TAK1","CHOP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H3M7","full_name":"Thioredoxin-interacting protein","aliases":["Thioredoxin-binding protein 2","Vitamin D3 up-regulated protein 1"],"length_aa":391,"mass_kda":43.7,"function":"May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability (PubMed:17603038). Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm (By similarity). Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest (PubMed:12821938). Required for the maturation of natural killer cells (By similarity). Acts as a suppressor of tumor cell growth (PubMed:18541147). Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1) (PubMed:21460850)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H3M7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TXNIP","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TXNIP","total_profiled":1310},"omim":[{"mim_id":"616464","title":"ECDYSONELESS CELL CYCLE REGULATOR; ECD","url":"https://www.omim.org/entry/616464"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"612464","title":"ARRESTIN DOMAIN-CONTAINING PROTEIN 3; ARRDC3","url":"https://www.omim.org/entry/612464"},{"mim_id":"606599","title":"THIOREDOXIN-INTERACTING PROTEIN; TXNIP","url":"https://www.omim.org/entry/606599"},{"mim_id":"603023","title":"IKAROS FAMILY ZINC FINGER 1; IKZF1","url":"https://www.omim.org/entry/603023"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TXNIP"},"hgnc":{"alias_symbol":["VDUP1","EST01027","HHCPA78","THIF","ARRDC6"],"prev_symbol":[]},"alphafold":{"accession":"Q9H3M7","domains":[{"cath_id":"2.60.40.640","chopping":"6-144","consensus_level":"high","plddt":87.595,"start":6,"end":144},{"cath_id":"2.60.40.640","chopping":"153-295","consensus_level":"high","plddt":90.7945,"start":153,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H3M7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H3M7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H3M7-F1-predicted_aligned_error_v6.png","plddt_mean":78.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TXNIP","jax_strain_url":"https://www.jax.org/strain/search?query=TXNIP"},"sequence":{"accession":"Q9H3M7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H3M7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H3M7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H3M7"}},"corpus_meta":[{"pmid":"24409188","id":"PMC_24409188","title":"Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24409188","citation_count":310,"is_preprint":false},{"pmid":"37394581","id":"PMC_37394581","title":"TXNIP: A key protein in the cellular stress response pathway and a potential therapeutic target.","date":"2023","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37394581","citation_count":256,"is_preprint":false},{"pmid":"12821938","id":"PMC_12821938","title":"VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12821938","citation_count":234,"is_preprint":false},{"pmid":"30197082","id":"PMC_30197082","title":"Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/30197082","citation_count":216,"is_preprint":false},{"pmid":"33190588","id":"PMC_33190588","title":"TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33190588","citation_count":183,"is_preprint":false},{"pmid":"28137209","id":"PMC_28137209","title":"TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook.","date":"2017","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/28137209","citation_count":180,"is_preprint":false},{"pmid":"22750447","id":"PMC_22750447","title":"Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer.","date":"2012","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/22750447","citation_count":148,"is_preprint":false},{"pmid":"29488135","id":"PMC_29488135","title":"Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29488135","citation_count":140,"is_preprint":false},{"pmid":"16607285","id":"PMC_16607285","title":"Hepatocellular carcinoma in Txnip-deficient mice.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16607285","citation_count":131,"is_preprint":false},{"pmid":"15723808","id":"PMC_15723808","title":"VDUP1 is required for the development of natural killer cells.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15723808","citation_count":123,"is_preprint":false},{"pmid":"15930262","id":"PMC_15930262","title":"Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15930262","citation_count":123,"is_preprint":false},{"pmid":"33302545","id":"PMC_33302545","title":"Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33302545","citation_count":119,"is_preprint":false},{"pmid":"24353900","id":"PMC_24353900","title":"Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.","date":"2013","source":"Journal of clinical & experimental ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/24353900","citation_count":110,"is_preprint":false},{"pmid":"17976314","id":"PMC_17976314","title":"Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases.","date":"2007","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17976314","citation_count":99,"is_preprint":false},{"pmid":"35450411","id":"PMC_35450411","title":"TXNIP: A Double-Edged Sword in Disease and Therapeutic Outlook.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35450411","citation_count":99,"is_preprint":false},{"pmid":"16301999","id":"PMC_16301999","title":"Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16301999","citation_count":99,"is_preprint":false},{"pmid":"30741672","id":"PMC_30741672","title":"Thioredoxin-Interacting Protein (TXNIP) Associated NLRP3 Inflammasome Activation in Human Alzheimer's Disease Brain.","date":"2019","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30741672","citation_count":97,"is_preprint":false},{"pmid":"21964212","id":"PMC_21964212","title":"TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms.","date":"2011","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21964212","citation_count":96,"is_preprint":false},{"pmid":"16388576","id":"PMC_16388576","title":"Structure of the Escherichia coli ThiS-ThiF complex, a key component of the sulfur transfer system in thiamin biosynthesis.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16388576","citation_count":93,"is_preprint":false},{"pmid":"28202418","id":"PMC_28202418","title":"ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28202418","citation_count":92,"is_preprint":false},{"pmid":"29356688","id":"PMC_29356688","title":"Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP.","date":"2018","source":"Current opinion in endocrinology, diabetes, and obesity","url":"https://pubmed.ncbi.nlm.nih.gov/29356688","citation_count":88,"is_preprint":false},{"pmid":"32824669","id":"PMC_32824669","title":"TXNIP/TBP-2: A Master Regulator for Glucose Homeostasis.","date":"2020","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32824669","citation_count":84,"is_preprint":false},{"pmid":"36299604","id":"PMC_36299604","title":"Corilagin Restrains NLRP3 Inflammasome Activation and Pyroptosis through the ROS/TXNIP/NLRP3 Pathway to Prevent Inflammation.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36299604","citation_count":82,"is_preprint":false},{"pmid":"12553030","id":"PMC_12553030","title":"Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease.","date":"2002","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12553030","citation_count":72,"is_preprint":false},{"pmid":"17550776","id":"PMC_17550776","title":"TXNIP links redox circuitry to glucose control.","date":"2007","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17550776","citation_count":72,"is_preprint":false},{"pmid":"33412212","id":"PMC_33412212","title":"TXNIP positively regulates the autophagy and apoptosis in the rat müller cell of diabetic retinopathy.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33412212","citation_count":69,"is_preprint":false},{"pmid":"37794178","id":"PMC_37794178","title":"The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37794178","citation_count":65,"is_preprint":false},{"pmid":"31173172","id":"PMC_31173172","title":"Role of TXNIP/NLRP3 in sepsis-induced myocardial dysfunction.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31173172","citation_count":63,"is_preprint":false},{"pmid":"18062927","id":"PMC_18062927","title":"VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18062927","citation_count":62,"is_preprint":false},{"pmid":"17040494","id":"PMC_17040494","title":"Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases.","date":"2006","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17040494","citation_count":61,"is_preprint":false},{"pmid":"25754218","id":"PMC_25754218","title":"Foam cell-derived 4-hydroxynonenal induces endothelial cell senescence in a TXNIP-dependent manner.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25754218","citation_count":56,"is_preprint":false},{"pmid":"26858253","id":"PMC_26858253","title":"Cytokines Regulate β-Cell Thioredoxin-interacting Protein (TXNIP) via Distinct Mechanisms and Pathways.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26858253","citation_count":54,"is_preprint":false},{"pmid":"31615975","id":"PMC_31615975","title":"Oxidative stress-mediated TXNIP loss causes RPE dysfunction.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31615975","citation_count":53,"is_preprint":false},{"pmid":"36881408","id":"PMC_36881408","title":"SIRT1 Inhibits High Glucose-Induced TXNIP/NLRP3 Inflammasome Activation and Cataract Formation.","date":"2023","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/36881408","citation_count":52,"is_preprint":false},{"pmid":"15896804","id":"PMC_15896804","title":"Structural analysis of Escherichia coli ThiF.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15896804","citation_count":52,"is_preprint":false},{"pmid":"35379773","id":"PMC_35379773","title":"AGE-TXNIP axis drives inflammation in Alzheimer's by targeting Aβ to mitochondria in microglia.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35379773","citation_count":51,"is_preprint":false},{"pmid":"31043707","id":"PMC_31043707","title":"UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31043707","citation_count":50,"is_preprint":false},{"pmid":"33567593","id":"PMC_33567593","title":"The Emerging Role of TXNIP in Ischemic and Cardiovascular Diseases; A Novel Marker and Therapeutic Target.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33567593","citation_count":49,"is_preprint":false},{"pmid":"11376942","id":"PMC_11376942","title":"Cloning, genetic characterization, and chromosomal mapping of the mouse VDUP1 gene.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11376942","citation_count":48,"is_preprint":false},{"pmid":"36448450","id":"PMC_36448450","title":"TXNIP Suppresses the Osteochondrogenic Switch of Vascular Smooth Muscle Cells in Atherosclerosis.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36448450","citation_count":44,"is_preprint":false},{"pmid":"37525261","id":"PMC_37525261","title":"Exercise-induced irisin improves follicular dysfunction by inhibiting IRE1α-TXNIP/ROS-NLRP3 pathway in PCOS.","date":"2023","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/37525261","citation_count":43,"is_preprint":false},{"pmid":"35562171","id":"PMC_35562171","title":"Energy restriction induced SIRT6 inhibits microglia activation and promotes angiogenesis in cerebral ischemia via transcriptional inhibition of TXNIP.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35562171","citation_count":42,"is_preprint":false},{"pmid":"30833078","id":"PMC_30833078","title":"TXNIP-mediated nuclear factor-κB signaling pathway and intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30833078","citation_count":42,"is_preprint":false},{"pmid":"36060506","id":"PMC_36060506","title":"TXNIP inhibition in the treatment of diabetes. Verapamil as a novel therapeutic modality in diabetic patients.","date":"2022","source":"Medicine and pharmacy reports","url":"https://pubmed.ncbi.nlm.nih.gov/36060506","citation_count":42,"is_preprint":false},{"pmid":"11579135","id":"PMC_11579135","title":"Rapid induction and Ca(2+) influx-mediated suppression of vitamin D3 up-regulated protein 1 (VDUP1) mRNA in cerebellar granule neurons undergoing apoptosis.","date":"2001","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11579135","citation_count":40,"is_preprint":false},{"pmid":"34350508","id":"PMC_34350508","title":"Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols.","date":"2021","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34350508","citation_count":37,"is_preprint":false},{"pmid":"30372683","id":"PMC_30372683","title":"Metabolic Syndrome, Brain Insulin Resistance, and Alzheimer's Disease: Thioredoxin Interacting Protein (TXNIP) and Inflammasome as Core Amplifiers.","date":"2018","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30372683","citation_count":36,"is_preprint":false},{"pmid":"39117021","id":"PMC_39117021","title":"Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome.","date":"2024","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39117021","citation_count":35,"is_preprint":false},{"pmid":"29684849","id":"PMC_29684849","title":"Mapping Txnip: Key connexions in progression of diabetic nephropathy.","date":"2017","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/29684849","citation_count":34,"is_preprint":false},{"pmid":"36271546","id":"PMC_36271546","title":"Calycosin modulates NLRP3 and TXNIP-mediated pyroptotic signaling and attenuates diabetic nephropathy progression in diabetic rats; An insight.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36271546","citation_count":33,"is_preprint":false},{"pmid":"31586460","id":"PMC_31586460","title":"Txnip mediates glucocorticoid-activated NLRP3 inflammatory signaling in mouse microglia.","date":"2019","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/31586460","citation_count":31,"is_preprint":false},{"pmid":"37689128","id":"PMC_37689128","title":"PIAS3 promotes ferroptosis by regulating TXNIP via TGF-β signaling pathway in hepatocellular carcinoma.","date":"2023","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/37689128","citation_count":30,"is_preprint":false},{"pmid":"12706526","id":"PMC_12706526","title":"Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species.","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12706526","citation_count":29,"is_preprint":false},{"pmid":"31578830","id":"PMC_31578830","title":"Sodium butyrate-activated TRAF6-TXNIP pathway affects A549 cells proliferation and migration.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31578830","citation_count":28,"is_preprint":false},{"pmid":"34461109","id":"PMC_34461109","title":"HOXA9-induced chemerin signals through CMKLR1/AMPK/TXNIP/NLRP3 pathway to induce pyroptosis of trophoblasts and aggravate preeclampsia.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34461109","citation_count":27,"is_preprint":false},{"pmid":"38329960","id":"PMC_38329960","title":"TXNIP-mediated crosstalk between oxidative stress and glucose metabolism.","date":"2024","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/38329960","citation_count":24,"is_preprint":false},{"pmid":"37116352","id":"PMC_37116352","title":"Memantine mitigates ROS/TXNIP/NLRP3 signaling and protects against mouse diabetic retinopathy: Histopathologic, ultrastructural and bioinformatic studies.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37116352","citation_count":23,"is_preprint":false},{"pmid":"34614512","id":"PMC_34614512","title":"TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34614512","citation_count":23,"is_preprint":false},{"pmid":"21151022","id":"PMC_21151022","title":"Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21151022","citation_count":22,"is_preprint":false},{"pmid":"33781783","id":"PMC_33781783","title":"Role and mechanism of TXNIP in ageing-related renal fibrosis.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/33781783","citation_count":22,"is_preprint":false},{"pmid":"20398702","id":"PMC_20398702","title":"Differential roles of Annexin A1 (ANXA1/lipocortin-1/lipomodulin) and thioredoxin binding protein-2 (TBP-2/VDUP1/TXNIP) in glucocorticoid signaling of HTLV-I-transformed T cells.","date":"2010","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/20398702","citation_count":22,"is_preprint":false},{"pmid":"36760500","id":"PMC_36760500","title":"PIN1 and PIN4 inhibition via parvulin impeders Juglone, PiB, ATRA, 6,7,4'-THIF, KPT6566, and EGCG thwarted hepatitis B virus replication.","date":"2023","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36760500","citation_count":21,"is_preprint":false},{"pmid":"34433833","id":"PMC_34433833","title":"Expression of TXNIP is associated with angiogenesis and postoperative relapse of conventional renal cell carcinoma.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34433833","citation_count":21,"is_preprint":false},{"pmid":"37153733","id":"PMC_37153733","title":"A novel NEDD4L-TXNIP-CHOP axis in the pathogenesis of nonalcoholic steatohepatitis.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37153733","citation_count":20,"is_preprint":false},{"pmid":"33748706","id":"PMC_33748706","title":"Dual regulation of TxNIP by ChREBP and FoxO1 in liver.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33748706","citation_count":20,"is_preprint":false},{"pmid":"36603341","id":"PMC_36603341","title":"Celastrol targets the ChREBP-TXNIP axis to ameliorates type 2 diabetes mellitus.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36603341","citation_count":20,"is_preprint":false},{"pmid":"40846790","id":"PMC_40846790","title":"Targeting MondoA-TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40846790","citation_count":19,"is_preprint":false},{"pmid":"38896955","id":"PMC_38896955","title":"The ROS/TXNIP/NLRP3 pathway mediates LPS-induced microglial inflammatory response.","date":"2024","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/38896955","citation_count":19,"is_preprint":false},{"pmid":"37749991","id":"PMC_37749991","title":"TXNIP activates NLRP3/IL-1β and participate in inflammatory response and oxidative stress to promote deep venous thrombosis.","date":"2023","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/37749991","citation_count":18,"is_preprint":false},{"pmid":"36517743","id":"PMC_36517743","title":"Ceramide induces pyroptosis through TXNIP/NLRP3/GSDMD pathway in HUVECs.","date":"2022","source":"BMC molecular and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36517743","citation_count":17,"is_preprint":false},{"pmid":"39102928","id":"PMC_39102928","title":"piR112710 attenuates diabetic cardiomyopathy through inhibiting Txnip/NLRP3-mediated pyroptosis in db/db mice.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/39102928","citation_count":17,"is_preprint":false},{"pmid":"38169654","id":"PMC_38169654","title":"TXNIP in liver sinusoidal endothelial cells ameliorates alcohol-associated liver disease via nitric oxide production.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38169654","citation_count":16,"is_preprint":false},{"pmid":"16143587","id":"PMC_16143587","title":"VDUP1: a potential mediator of expansion-induced lung growth and epithelial cell differentiation in the ovine fetus.","date":"2005","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16143587","citation_count":16,"is_preprint":false},{"pmid":"35240955","id":"PMC_35240955","title":"Overview on Thioredoxin-Interacting Protein (TXNIP): A Potential Target for Diabetes Intervention.","date":"2022","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/35240955","citation_count":16,"is_preprint":false},{"pmid":"33652022","id":"PMC_33652022","title":"Txnip C247S mutation protects the heart against acute myocardial infarction.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33652022","citation_count":15,"is_preprint":false},{"pmid":"39153986","id":"PMC_39153986","title":"PTBP1 knockdown impairs autophagy flux and inhibits gastric cancer progression through TXNIP-mediated oxidative stress.","date":"2024","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/39153986","citation_count":14,"is_preprint":false},{"pmid":"34478732","id":"PMC_34478732","title":"TXNIP interaction with GLUT1 depends on PI(4,5)P2.","date":"2021","source":"Biochimica et biophysica acta. Biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/34478732","citation_count":14,"is_preprint":false},{"pmid":"34726138","id":"PMC_34726138","title":"DNA Methylation of TXNIP Independently Associated with Inflammation and Diabetes Mellitus in Twins.","date":"2021","source":"Twin research and human genetics : the official journal of the International Society for Twin Studies","url":"https://pubmed.ncbi.nlm.nih.gov/34726138","citation_count":14,"is_preprint":false},{"pmid":"27437069","id":"PMC_27437069","title":"Identification of Redox and Glucose-Dependent Txnip Protein Interactions.","date":"2016","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/27437069","citation_count":14,"is_preprint":false},{"pmid":"39982519","id":"PMC_39982519","title":"FOXO regulation of TXNIP induces ferroptosis in satellite cells by inhibiting glutathione metabolism, promoting Sarcopenia.","date":"2025","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39982519","citation_count":13,"is_preprint":false},{"pmid":"19824090","id":"PMC_19824090","title":"Expression and regulation of vitamin D3 upregulated protein 1 (VDUP1) is conserved in mammalian and insect brain.","date":"2009","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19824090","citation_count":13,"is_preprint":false},{"pmid":"37534934","id":"PMC_37534934","title":"USP5 promotes lipopolysaccharide-induced apoptosis and inflammatory response by stabilizing the TXNIP protein.","date":"2023","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/37534934","citation_count":13,"is_preprint":false},{"pmid":"30037981","id":"PMC_30037981","title":"Ras Suppresses TXNIP Expression by Restricting Ribosome Translocation.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30037981","citation_count":13,"is_preprint":false},{"pmid":"37506869","id":"PMC_37506869","title":"DNMT1 regulates miR-20a/TXNIP-mediated pyroptosis of retinal pigment epithelial cells through DNA methylation.","date":"2023","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37506869","citation_count":13,"is_preprint":false},{"pmid":"37038114","id":"PMC_37038114","title":"High TXNIP expression accelerates the migration and invasion of the GDM placenta trophoblast.","date":"2023","source":"BMC pregnancy and childbirth","url":"https://pubmed.ncbi.nlm.nih.gov/37038114","citation_count":12,"is_preprint":false},{"pmid":"35771146","id":"PMC_35771146","title":"Galectin-3 induces vascular smooth muscle cells calcification via AMPK/TXNIP pathway.","date":"2022","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/35771146","citation_count":12,"is_preprint":false},{"pmid":"36930677","id":"PMC_36930677","title":"TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding.","date":"2023","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/36930677","citation_count":11,"is_preprint":false},{"pmid":"32799209","id":"PMC_32799209","title":"The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.","date":"2020","source":"Dermatology (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32799209","citation_count":11,"is_preprint":false},{"pmid":"34855213","id":"PMC_34855213","title":"Antidiabetic effects of quercetin and liraglutide combination through modulation of TXNIP/IRS-1/PI3K pathway.","date":"2021","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/34855213","citation_count":11,"is_preprint":false},{"pmid":"38047987","id":"PMC_38047987","title":"Narirutin Attenuates Cerebral Ischemia-Reperfusion Injury by Suppressing the TXNIP/NLRP3 Pathway.","date":"2023","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/38047987","citation_count":11,"is_preprint":false},{"pmid":"31320475","id":"PMC_31320475","title":"ERK-dependent proteasome degradation of Txnip regulates thioredoxin oxidoreductase activity.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31320475","citation_count":11,"is_preprint":false},{"pmid":"35887091","id":"PMC_35887091","title":"Targeted Induction of Endogenous VDUP1 by Small Activating RNA Inhibits the Growth of Lung Cancer Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35887091","citation_count":10,"is_preprint":false},{"pmid":"36289253","id":"PMC_36289253","title":"MicroRNA-25-5p negatively regulates TXNIP expression and relieves inflammatory responses of brain induced by lipopolysaccharide.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36289253","citation_count":10,"is_preprint":false},{"pmid":"31669268","id":"PMC_31669268","title":"Thioredoxin interacting protein (Txnip) forms redox sensitive high molecular weight nucleoprotein complexes.","date":"2019","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/31669268","citation_count":10,"is_preprint":false},{"pmid":"35820305","id":"PMC_35820305","title":"Celastrol inhibits TXNIP expression to protect pancreatic β cells in diabetic mice.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35820305","citation_count":10,"is_preprint":false},{"pmid":"31993438","id":"PMC_31993438","title":"Glucose-6-Phosphate Upregulates Txnip Expression by Interacting With MondoA.","date":"2020","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31993438","citation_count":10,"is_preprint":false},{"pmid":"37742607","id":"PMC_37742607","title":"SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37742607","citation_count":10,"is_preprint":false},{"pmid":"37290673","id":"PMC_37290673","title":"Depletion of pyruvate kinase (PK) activity causes glycolytic intermediate imbalances and reveals a PK-TXNIP regulatory axis.","date":"2023","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37290673","citation_count":10,"is_preprint":false},{"pmid":"34968780","id":"PMC_34968780","title":"YAP/miR-524-5p axis negatively regulates TXNIP expression to promote chondrosarcoma cell growth.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34968780","citation_count":9,"is_preprint":false},{"pmid":"37555854","id":"PMC_37555854","title":"Effects of evodiamine on ROS/TXNIP/NLRP3 pathway against gouty arthritis.","date":"2023","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37555854","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52259,"output_tokens":8039,"usd":0.138681,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17686,"output_tokens":5059,"usd":0.107453,"stage2_stop_reason":"end_turn"},"total_usd":0.246134,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"VDUP1/TXNIP interacts with promyelocytic leukemia zinc-finger (PLZF), Fanconi anemia zinc-finger (FAZF), and histone deacetylase 1 (HDAC1), forming a transcriptional repressor complex that suppresses IL-3 receptor and cyclin A2 promoter activity, causing G0/G1 cell-cycle arrest.\",\n      \"method\": \"Co-immunoprecipitation, transfection/overexpression, reporter assays, cell-cycle analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — co-IP and reporter assays from single lab, multiple orthogonal methods confirming transcriptional repressor complex\",\n      \"pmids\": [\"12821938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"VDUP1/TXNIP interacts with JAB1 (CSN5) and blocks JAB1-mediated nuclear-to-cytoplasm translocation of p27(kip1), thereby stabilizing p27 and inhibiting cell proliferation. VDUP1-/- fibroblasts show reduced p27 and increased proliferation.\",\n      \"method\": \"Co-immunoprecipitation, VDUP1-/- fibroblast analysis, subcellular fractionation, cell proliferation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal co-IP plus KO model with defined molecular phenotype, single lab\",\n      \"pmids\": [\"15930262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"VDUP1/TXNIP is required for NK cell development in vivo; VDUP1-/- mice show profound reduction in NK cell numbers and decreased NK activity, with reduced CD122 expression demonstrating that VDUP1 is required for CD122 expression and NK maturation.\",\n      \"method\": \"VDUP1-/- mouse model, flow cytometry, NK cytotoxicity assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with defined cellular phenotype, flow cytometry, multiple readouts in one study\",\n      \"pmids\": [\"15723808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TXNIP is a glucocorticoid receptor primary response gene; a functional glucocorticoid response element (GRE) in the TXNIP promoter mediates dexamethasone-induced transcription, and TXNIP expression is sufficient to induce apoptosis in T lymphoma cells; RNAi knockdown of TXNIP inhibits glucocorticoid-induced apoptosis.\",\n      \"method\": \"Promoter deletion/mutation analysis, reporter assays, GFP-TXNIP overexpression, siRNA knockdown, Northern blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — promoter mutagenesis with reporter assays plus loss- and gain-of-function in the same study, single lab\",\n      \"pmids\": [\"16301999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Txnip deficiency in mice (HcB-19 strain with spontaneous Txnip mutation) causes spontaneous hepatocellular carcinoma (~40% incidence), with increased alpha-fetoprotein and p53, demonstrating Txnip is a tumor suppressor gene required in vivo to prevent HCC.\",\n      \"method\": \"Recombinant inbred congenic mouse model, cosegregation analysis, histology, BrdU labeling, microarray\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic cosegregation in congenic strain, histological confirmation, multiple molecular markers\",\n      \"pmids\": [\"16607285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"VDUP1/TXNIP associates with the beta-domain of pVHL, enhances the pVHL–HIF1α interaction, and promotes CRM1-dependent nuclear export and degradation of HIF1α, suppressing cell invasiveness and tumor metastasis. Blocking VDUP1 nuclear export with leptomycin B or NES mutation inhibits HIF1α destabilization.\",\n      \"method\": \"Co-immunoprecipitation, nuclear export inhibition (leptomycin B), NES mutation, invasion/metastasis assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — co-IP with VHL, pharmacological and genetic blockade of export, single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"18062927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IL-1β down-regulates TXNIP transcription via inhibition of carbohydrate response element binding protein (ChREBP) activity, while IFNγ increases TXNIP post-transcriptionally by inducing ER stress, activating IRE1α, and suppressing miR-17, a microRNA that targets TXNIP mRNA. miR-17 knockdown mimics IFNγ effects on TXNIP; miR-17 overexpression blunts IFNγ-induced TXNIP elevation.\",\n      \"method\": \"TXNIP promoter analysis, chromatin immunoprecipitation (ChIP), miR-17 overexpression/knockdown, IRE1α inhibition, primary islet studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP, promoter analysis, miRNA gain/loss-of-function, validated in both INS-1 cells and primary islets in single study\",\n      \"pmids\": [\"26858253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hyaluronan/ECM remodeling triggers receptor tyrosine kinase-mediated induction of the mRNA decay factor ZFP36, which targets TXNIP transcripts for degradation; acute TXNIP decline enriches GLUT1 at the plasma membrane because TXNIP normally promotes internalization (endocytosis) of GLUT1, thereby increasing glycolysis and cell migration.\",\n      \"method\": \"Unbiased glycolytic driver screen, hyaluronidase treatment of cells and xenografts, ZFP36 induction assays, GLUT1 surface trafficking analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (mRNA decay assay, surface GLUT1 quantification, xenograft validation), replicated across cell types and in vivo\",\n      \"pmids\": [\"30197082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TXNIP directly interacts with and positively regulates phosphorylated AMPK (p-PRKAA), leading to inactivation of mTORC1 and nuclear translocation of TFEB, which promotes autophagy and fatty acid oxidation. Txnip-KO mice show impaired autophagy and fatty acid oxidation; rapamycin rescues this phenotype.\",\n      \"method\": \"Co-immunoprecipitation (TXNIP–AMPK), txnip-KO mice, rapamycin rescue, Atg7 silencing epistasis, nuclear TFEB localization\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus KO mouse model with mechanistic rescue, single lab\",\n      \"pmids\": [\"33190588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK MAPK phosphorylates TXNIP at Thr349 within a PXTP motif in its C-terminal α-arrestin domain, triggering ubiquitination and proteasomal degradation of TXNIP, thereby releasing thioredoxin oxidoreductase activity; ERK inhibition augments intracellular ROS and S-nitrosothiols.\",\n      \"method\": \"ERK inhibitor pharmacology, site-directed mutagenesis of Thr349, ubiquitination assay, proteasome inhibition, ROS/S-nitrosothiol measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of phospho-site plus ubiquitination assay plus functional ROS readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31320475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TXNIP interacts with and shifts intracellularly from the nucleus to mitochondria under oxidative stress (MSU crystals); TXNIP directly binds NLRP3 under these conditions to activate the NLRP3 inflammasome and NF-κB signaling; antioxidants and TXNIP siRNA block this interaction and suppress inflammasome activation.\",\n      \"method\": \"Western blot, co-immunoprecipitation, TXNIP siRNA, subcellular fractionation, immunofluorescence localization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP for TXNIP–NLRP3 interaction plus siRNA knockdown with functional inflammasome readout, single lab\",\n      \"pmids\": [\"30833078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TXNIP nucleoprotein complex: TXNIP forms redox-sensitive high molecular weight complexes (~1000–1300 kDa) in the nuclear fraction, partially dissolved by DTT; binding partners identified by tandem affinity purification and proteomics include HSP90, HSP70, and Prp31.\",\n      \"method\": \"Tandem affinity purification, proteomics (MS), native PAGE, DTT disruption, RNAse treatment\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics + native PAGE + chemical disruption evidence for redox-sensitive complex, single lab\",\n      \"pmids\": [\"31669268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TXNIP interacts with GLUT1 in a 1:1 ratio, and this interaction requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2); TXNIP acts as an adaptor for GLUT1 in clathrin-mediated endocytosis to reduce glucose uptake, using its C-terminal arrestin domain and di-leucine endocytic motif.\",\n      \"method\": \"GLUT1 lipid nanodiscs, isothermal titration calorimetry (ITC), single-particle electron microscopy, PIP2 requirement tested\",\n      \"journal\": \"Biochimica et biophysica acta. Biomembranes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with nanodiscs, ITC (quantitative binding), electron microscopy, identification of lipid cofactor requirement in single study\",\n      \"pmids\": [\"34478732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Txnip C247S mutation abolishes disulfide bond formation with thioredoxin; cardiomyocyte-specific C247S knock-in mice have smaller infarct sizes after myocardial infarction with reduced ROS, demonstrating that Txnip's inhibition of thioredoxin via C247 disulfide is required for its pro-oxidative, cytotoxic effects in the heart.\",\n      \"method\": \"Site-directed mutagenesis, conditional knock-in mouse model, ROS measurement, infarct size quantification, RNA-seq\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis of catalytic cysteine in vivo with conditional knock-in model and multiple functional readouts\",\n      \"pmids\": [\"33652022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Txnip directly binds STAT3 (confirmed by co-immunoprecipitation) and activates the STAT3 signaling pathway in renal tubular epithelial cells, thereby promoting a profibrotic response and accelerating renal aging; STAT3 inhibitor blocks TXNIP-mediated fibrosis.\",\n      \"method\": \"Co-immunoprecipitation, TXNIP overexpression/siRNA in tubular cells, TXNIP-KO mice, STAT3 inhibitor rescue\",\n      \"journal\": \"Mechanisms of ageing and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single co-IP plus KO mouse model and pharmacological rescue, single lab\",\n      \"pmids\": [\"33781783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Corticosterone (chronic stress hormone) increases TXNIP protein and TXNIP–NLRP3 binding in microglia; CRISPR/Cas9 knockout of Txnip inhibits corticosterone-induced caspase-1 activity and IL-1β release, placing Txnip upstream of the NLRP3 inflammasome in corticosterone-induced neuroinflammation.\",\n      \"method\": \"Co-immunoprecipitation (TXNIP–NLRP3), CRISPR/Cas9 Txnip knockout, caspase-1 activity assay, ELISA for IL-1β\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — CRISPR KO with defined functional readout and co-IP, single lab\",\n      \"pmids\": [\"31586460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SIRT6 transcriptionally suppresses TXNIP by deacetylating H3K9ac and H3K56ac at the TXNIP locus (confirmed by ChIP), reducing TXNIP expression and thereby inhibiting microglial activation and promoting angiogenesis in cerebral ischemia.\",\n      \"method\": \"ChIP assay for SIRT6 occupancy and H3 deacetylation, SIRT6 overexpression, energy restriction diet model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with histone mark validation plus SIRT6 overexpression in cell and in vivo models, single lab\",\n      \"pmids\": [\"35562171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIAS3 interacts with SMAD2/3 to activate TGF-β signaling, increasing TXNIP expression; TXNIP is required downstream of PIAS3 for ferroptotic cell death in hepatocellular carcinoma cells. TXNIP knockdown reduces PIAS3-overexpression-induced ferroptosis; forced TXNIP re-expression restores ferroptosis sensitivity.\",\n      \"method\": \"TMT-based proteomics, RNA-seq, co-immunoprecipitation (PIAS3–SMAD2/3), TXNIP knockdown/overexpression, ferroptosis assays\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — co-IP, epistatic rescue experiments, two orthogonal methods, single lab\",\n      \"pmids\": [\"37689128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SIRT1 acts as an upstream negative regulator of TXNIP/NLRP3 inflammasome activity in lens epithelial cells under high glucose; si-SIRT1 and LV-SIRT1 had inverse effects on NLRP3 inflammasome activation, and TXNIP knockdown inhibited NLRP3-induced IL-1β secretion.\",\n      \"method\": \"siRNA knockdown, lentiviral overexpression, NLRP3/TXNIP siRNA, Western blot, ROS measurement in HLECs and ex vivo rat lenses\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal gain/loss-of-function for SIRT1 and TXNIP, two cell models, single lab\",\n      \"pmids\": [\"36881408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TXNIP suppresses the osteochondrogenic transition of vascular smooth muscle cells (VSMCs) by inhibiting BMP signaling; smooth-muscle-specific Txnip knockout (Tagln-Cre; Txnip-flox) recapitulates increased atherosclerotic calcification and expanded osteochondrogenic clusters; BMP inhibitor K02288 abrogates the effect of TXNIP suppression on osteodifferentiation.\",\n      \"method\": \"Conditional VSMC-specific KO mice, single-cell RNA-seq, BMP inhibitor rescue, primary VSMC culture with TXNIP suppression\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with scRNA-seq pathway analysis, pharmacological rescue, and human data reanalysis\",\n      \"pmids\": [\"36448450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NEDD4L is the E3 ubiquitin ligase responsible for TXNIP ubiquitination and proteasomal degradation in hepatocytes; decreased NEDD4L in NASH leads to impaired TXNIP ubiquitination and accumulation of TXNIP protein. TXNIP C-terminus associates with the α-helix domain N-terminus of CHOP, decreasing CHOP ubiquitination and stabilizing CHOP protein to drive ER stress-mediated apoptosis.\",\n      \"method\": \"Four NASH mouse models, E3 ligase screen, co-immunoprecipitation (TXNIP–CHOP), ubiquitination assay, adenovirus-mediated shRNA KD, gain/loss-of-function studies\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reconstitution of ubiquitination pathway, co-IP of TXNIP–CHOP, multiple NASH models, mechanistic rescue, single lab with many orthogonal methods\",\n      \"pmids\": [\"37153733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TXNIP shuttles between thioredoxin (TRX) and class I GLUTs (GLUT1–4) depending on intracellular ROS levels; elevated ROS shifts TXNIP from TRX to GLUTs via the C-terminal arrestin (C-ARR) domain; TXNIP then promotes lysosomal degradation of GLUTs through its di-leucine endocytic motif, reducing glucose uptake and suppressing glycolysis, hexosamine biosynthesis, and the pentose phosphate pathway.\",\n      \"method\": \"Co-immunoprecipitation, domain-swap/deletion mutants, ROS manipulation, GLUT surface expression, lysosomal inhibition, metabolic flux assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple co-IP experiments with mutants identifying C-ARR domain, lysosomal pathway confirmed, metabolic readouts, single lab\",\n      \"pmids\": [\"38329960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"USP5 deubiquitylase interacts with TXNIP (confirmed by co-immunoprecipitation) and stabilizes TXNIP by removing its ubiquitin modifications; USP5 knockdown reduces TXNIP levels, increases cell viability, and decreases inflammasome/apoptotic signaling in LPS-treated hepatocytes.\",\n      \"method\": \"Overexpression screen for deubiquitinase stabilizing TXNIP, co-immunoprecipitation, siRNA knockdown, ubiquitination assay\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP screen plus KD rescue, single lab, identifies specific DUB\",\n      \"pmids\": [\"37534934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SIRT1 deacetylates H3K9 at the TXNIP promoter (demonstrated by ChIP-qPCR) to repress TXNIP transcription; exenatide (exendin-4) upregulates SIRT1, which reduces TXNIP H3K9ac and decreases XBP1s recruitment to the TXNIP promoter, lowering TXNIP expression and protecting against diabetic kidney disease.\",\n      \"method\": \"ChIP-qPCR, whole-body and kidney-specific Sirt1 KO mice, exendin-4 treatment, XBP1s recruitment analysis\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR for histone modification plus conditional KO mice, single lab\",\n      \"pmids\": [\"37742607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Txnip BioID proximity labeling identified 31 interacting proteins; many interactions were disrupted by C247S mutation, demonstrating redox-dependent binding; hyperglycemia dynamically alters Txnip interactions, revealing that Txnip's pleiotropic functions are mediated through distinct, condition-specific protein complexes.\",\n      \"method\": \"BioID proximity labeling fused to Txnip in HEK293 cells, C247S mutant comparison, mass spectrometry\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity labeling proteomics with reactive cysteine mutant to distinguish redox-dependent interactions, single lab\",\n      \"pmids\": [\"27437069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Oncogenic Ras suppresses TXNIP protein synthesis by reducing ribosome transit rate along the TXNIP mRNA coding region (translational elongation); the N-terminal nascent TXNIP polypeptide is the target for Ras-dependent translational repression, independent of codon usage, mRNA secondary structure, or miRNAs.\",\n      \"method\": \"Ribosome profiling-based translational elongation assay, codon-randomized/optimized TXNIP mRNA variants, N-terminal truncation mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ribosome transit assay plus mutagenesis of mRNA sequence variants to dissect mechanism, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"30037981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ChREBP and FoxO1 both up-regulate TxNIP expression in hepatocytes; genetic studies in mice with liver-specific deletion of ChREBP or FoxO1 show that both transcription factors are required for full TxNIP induction in response to glucose and fasting, respectively.\",\n      \"method\": \"Genetically modified mice (ChREBP and FoxO1 liver-specific models), gene expression analysis, db/db hyperglycemia model\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent genetic mouse models identifying dual transcriptional regulators, single lab\",\n      \"pmids\": [\"33748706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Glucose-6-phosphate (G6P) directly activates the transcription factor heterodimer MondoA/Mlx to upregulate TXNIP expression; EMSA and endogenous knockdown confirmed G6P (not glucose itself) as the activating metabolic intermediate. Mutational analysis of MondoA identified GKL139-141 residues as mediating G6P binding.\",\n      \"method\": \"EMSA (gel mobility shift), endogenous knockdown of MondoA, molecular docking, mutational analysis of MondoA binding residues\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus mutagenesis to identify G6P binding residues in MondoA, single lab\",\n      \"pmids\": [\"31993438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MondoA-induced TXNIP transcription is activated by lactic acid via SENP1-dependent deSUMOylation of MondoA; in CD8+ T cells, the MondoA–TXNIP axis impairs TCR/CD28 signaling-induced activation by reducing glucose uptake and glycolysis; in Treg cells, TXNIP promotes immunosuppressive function.\",\n      \"method\": \"MondoA-deficient T cell models, glucose uptake assays, TCR activation assays, tumor immunotherapy models with anti-PD-1 combination\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic MondoA deletion in two T cell subsets, mechanistic pathway identification via SENP1, validated in multiple cancer models with combination therapy\",\n      \"pmids\": [\"40846790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TXNIP interacts with TAK1 (transforming growth factor β-activated kinase 1) in liver sinusoidal endothelial cells (LSECs) and suppresses the TAK1 pathway, thereby maintaining nitric oxide (NO) production; endothelial Txnip deletion leads to sinusoidal capillarization, reduced NO, increased pro-inflammatory cytokines, and aggravated alcohol-associated liver disease.\",\n      \"method\": \"Co-immunoprecipitation (TXNIP–TAK1), endothelial-specific Txnip KO mice, TXNIP overexpression in LSECs, TAK1 inhibitor rescue\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — co-IP identifying novel partner, cell-type-specific KO with pharmacological rescue, single lab\",\n      \"pmids\": [\"38169654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Elevated TXNIP in RPE cells undergoes downregulation under oxidative stress; TXNIP knockdown induces autophagic flux causing nuclear localization of p53, enhanced AMPK phosphorylation, disruption of tight junctions (via Src kinase phosphorylation), and increased HIF-1α leading to VEGF secretion from RPE cells.\",\n      \"method\": \"TXNIP siRNA knockdown in RPE cells, autophagy flux assay, subcellular localization of p53, Src kinase activity measurement, VEGF ELISA, co-culture angiogenesis assay\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA knockdown with multiple downstream readouts in single lab identifying mechanistic cascade\",\n      \"pmids\": [\"31615975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TXNIP loss in MDA-MB-231 TNBC cells increases global Myc genome occupancy, allowing Myc to invade promoters and enhancers of additional target genes, expanding the Myc-dependent transcriptome without increasing Myc protein levels or Myc's intrinsic transcriptional activity.\",\n      \"method\": \"TXNIP null (CRISPR KO) MDA-MB-231 cells, ChIP-seq for Myc genome-wide occupancy, RNA-seq\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — genome-wide ChIP-seq plus RNA-seq in CRISPR KO cells demonstrating mechanistic link between TXNIP loss and Myc occupancy, single lab\",\n      \"pmids\": [\"36930677\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TXNIP is a multifunctional α-arrestin scaffold protein that inhibits thioredoxin antioxidant activity via a C247 disulfide bond, promotes lysosomal degradation of GLUT1-4 through its C-ARR domain and di-leucine endocytic motif (requiring PI(4,5)P2) to limit glucose uptake, activates the NLRP3 inflammasome by directly binding NLRP3 under oxidative stress, suppresses tumor progression by stabilizing p27 (via JAB1 inhibition), facilitating HIF1α nuclear export and degradation (via pVHL), and broadly restraining Myc genomic occupancy; its expression is transcriptionally controlled by glucose-6-phosphate/MondoA-Mlx, ChREBP, FoxO1, glucocorticoid receptor, and SIRT6/SIRT1-dependent histone deacetylation, and its protein stability is regulated by ERK-phosphorylation at Thr349 driving NEDD4L/ubiquitin-proteasomal degradation or USP5-mediated stabilization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TXNIP is a redox-responsive α-arrestin scaffold that couples cellular oxidative and metabolic state to glucose handling, antioxidant capacity, inflammation, and cell-fate decisions [#21, #24]. Its defining redox switch is the C247 disulfide bond with thioredoxin: this cysteine-dependent inhibition of thioredoxin oxidoreductase drives pro-oxidative, cytotoxic outcomes, and a cardiomyocyte C247S knock-in limits infarct size with reduced ROS [#13]. Rising ROS releases TXNIP from thioredoxin and redirects it through its C-terminal arrestin (C-ARR) domain and di-leucine endocytic motif onto class I glucose transporters GLUT1–4, which TXNIP internalizes (binding GLUT1 in a 1:1, PI(4,5)P2-dependent manner) and routes to lysosomal degradation, thereby restraining glucose uptake, glycolysis, the hexosamine and pentose phosphate pathways [#12, #21]. TXNIP additionally acts as a tumor suppressor: it is required in vivo to prevent hepatocellular carcinoma, stabilizes p27(kip1) by blocking JAB1/CSN5-mediated nuclear export, promotes pVHL/CRM1-dependent nuclear export and degradation of HIF1α to suppress invasion, and restrains genome-wide Myc occupancy [#4, #1, #5, #31]. Under oxidative stress TXNIP relocates and directly binds NLRP3 to activate the inflammasome and downstream caspase-1/IL-1β release, linking it to gout, glucocorticoid/corticosterone, and high-glucose inflammatory responses [#10, #15, #18]. It also engages signaling and stability partners including AMPK (driving mTORC1 inactivation, TFEB nuclear translocation, autophagy and fatty acid oxidation), STAT3, TAK1, and CHOP, the last stabilized by TXNIP to promote ER-stress apoptosis [#8, #14, #29, #20]. TXNIP abundance is set by extensive transcriptional control via glucose-6-phosphate/MondoA-Mlx, ChREBP, FoxO1, the glucocorticoid receptor, and SIRT6/SIRT1-dependent histone deacetylation, and by post-translational stability control through ERK phosphorylation at Thr349, NEDD4L-mediated ubiquitination, and USP5-mediated deubiquitination [#27, #26, #3, #16, #23, #9, #20, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established an early function for TXNIP as a transcriptional co-repressor controlling cell-cycle exit, the first hint that it acts as a scaffold within nuclear complexes.\",\n      \"evidence\": \"Co-IP, reporter and cell-cycle assays linking TXNIP to PLZF/FAZF/HDAC1 repression of IL-3 receptor and cyclin A2\",\n      \"pmids\": [\"12821938\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA binding by TXNIP not demonstrated\", \"Physiological relevance outside overexpression unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined how TXNIP restrains proliferation, by stabilizing the CDK inhibitor p27 through inhibition of JAB1-driven nuclear export, and showed it is required for NK cell maturation in vivo.\",\n      \"evidence\": \"Reciprocal co-IP and VDUP1-/- fibroblasts (p27); VDUP1-/- mice and flow cytometry (NK/CD122)\",\n      \"pmids\": [\"15930262\", \"15723808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p27 and NK phenotypes share a single molecular mechanism unresolved\", \"Structural basis of JAB1 inhibition not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that TXNIP is a glucocorticoid-receptor primary response gene mediating apoptosis and a bona fide tumor suppressor required to prevent hepatocellular carcinoma in vivo.\",\n      \"evidence\": \"GRE promoter mutagenesis with gain/loss-of-function (Oncogene 2006); HcB-19 Txnip-mutant congenic mice with HCC cosegregation\",\n      \"pmids\": [\"16301999\", \"16607285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular effectors of TXNIP-driven apoptosis not defined in 2006\", \"Link between tumor suppression and redox/metabolic functions not yet made\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected TXNIP to hypoxia signaling and metastasis suppression by showing it enhances pVHL–HIF1α interaction and promotes CRM1-dependent nuclear export/degradation of HIF1α.\",\n      \"evidence\": \"Co-IP with pVHL, leptomycin B and NES-mutant export blockade, invasion/metastasis assays\",\n      \"pmids\": [\"18062927\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs scaffolded contribution to HIF1α degradation not separated\", \"In vivo metastasis dependence on this axis not genetically tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved how inflammatory cytokines tune TXNIP, with IL-1β repressing ChREBP-driven transcription and IFNγ raising TXNIP post-transcriptionally via IRE1α/miR-17.\",\n      \"evidence\": \"ChIP, promoter analysis, miR-17 gain/loss-of-function and IRE1α inhibition in INS-1 cells and primary islets\",\n      \"pmids\": [\"26858253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of opposing cytokine inputs on net TXNIP level in vivo unclear\", \"Whether miR-17 directly binds TXNIP 3'UTR shown only indirectly\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established TXNIP as a direct adaptor for GLUT1 internalization and identified two distinct upstream controls — ZFP36-mediated mRNA decay and Ras-mediated translational elongation repression — that lower TXNIP to boost glycolysis.\",\n      \"evidence\": \"Glycolytic driver screen, ZFP36 mRNA-decay and surface-GLUT1 assays, xenografts (Cell 2018); ribosome transit assays and mRNA/N-terminal mutants (MCB 2018)\",\n      \"pmids\": [\"30197082\", \"30037981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether elongation control and decay act on the same TXNIP pool unknown\", \"Endocytic machinery for GLUT1 internalization not yet structurally defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped multiple regulatory and effector arms: ERK-Thr349 phosphorylation triggering proteasomal degradation, direct NLRP3 binding to activate the inflammasome, AMPK–mTORC1–TFEB control of autophagy, and a redox-dependent BioID interactome.\",\n      \"evidence\": \"Thr349 mutagenesis/ubiquitination/ROS assays; TXNIP–NLRP3 co-IP and siRNA; TXNIP–AMPK co-IP with Txnip-KO and rapamycin rescue; BioID with C247S comparison\",\n      \"pmids\": [\"31320475\", \"30833078\", \"33190588\", \"27437069\", \"31615975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether single TXNIP molecule scaffolds multiple effectors or pools partition by condition unresolved\", \"Direct NLRP3 binding interface not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided biophysical and genetic anchors for core mechanisms: reconstituted 1:1 PI(4,5)P2-dependent TXNIP–GLUT1 binding, and an in vivo C247S knock-in proving the thioredoxin disulfide drives pro-oxidative cardiac injury; expanded the partner set to STAT3 and nuclear HMW redox complexes.\",\n      \"evidence\": \"GLUT1 nanodiscs, ITC and EM (BBA Biomembranes); cardiac C247S knock-in with ROS/infarct readouts; STAT3 co-IP with KO/inhibitor; tandem-affinity proteomics (HSP90/HSP70/Prp31)\",\n      \"pmids\": [\"34478732\", \"33652022\", \"33781783\", \"31669268\", \"33748706\", \"31586460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and composition of nuclear HMW complexes not fully defined\", \"STAT3 and TAK1 binding interfaces not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended transcriptional control via SIRT6 histone deacetylation and identified context-specific roles in vascular calcification (BMP suppression), ferroptosis (downstream of PIAS3/TGF-β), and inflammasome regulation by SIRT1.\",\n      \"evidence\": \"SIRT6 ChIP with H3K9/H3K56ac; VSMC-specific Txnip KO with scRNA-seq and BMP inhibitor rescue; PIAS3–SMAD2/3 co-IP with TXNIP epistasis; SIRT1 gain/loss in lens epithelium\",\n      \"pmids\": [\"35562171\", \"36448450\", \"37689128\", \"36881408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TXNIP toggles between pro-survival and pro-death outputs not mechanistically unified\", \"Direct molecular target through which TXNIP modulates BMP signaling unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Consolidated the ROS-gated TRX-to-GLUT shuttling model, defined the NEDD4L–USP5 ubiquitin/deubiquitin axis (and CHOP stabilization), added SIRT1/XBP1s promoter control, and revealed TXNIP restrains genome-wide Myc occupancy and shapes T-cell metabolism via MondoA.\",\n      \"evidence\": \"Domain-swap co-IP and metabolic flux (PLoS ONE); NEDD4L E3 screen and TXNIP–CHOP co-IP across NASH models; USP5 DUB screen; SIRT1 ChIP-qPCR/XBP1s; Myc ChIP-seq/RNA-seq in CRISPR-KO TNBC; MondoA-deletion T cells with SENP1 axis\",\n      \"pmids\": [\"38329960\", \"37153733\", \"37534934\", \"37742607\", \"36930677\", \"40846790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which TXNIP loss permits Myc promoter/enhancer invasion is unresolved\", \"Whether GLUT-binding and Myc-restraining functions are linked unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Added an endothelial protective role in which TXNIP suppresses TAK1 to preserve nitric oxide and limit liver sinusoidal capillarization.\",\n      \"evidence\": \"TXNIP–TAK1 co-IP, endothelial-specific Txnip KO, overexpression and TAK1 inhibitor rescue in LSECs\",\n      \"pmids\": [\"38169654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TAK1 binding interface and whether inhibition is direct vs scaffolded not defined\", \"Single-lab co-IP without reciprocal structural validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying structural and biochemical model explaining how one redox-sensing α-arrestin partitions among thioredoxin, GLUT transporters, NLRP3, p27/JAB1, HIF1α, and Myc-restraining functions across cell types remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of full-length TXNIP bound to its major partners\", \"Rules governing condition-specific complex selection not established\", \"Direct DNA/chromatin relationship underlying Myc restraint unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [12, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [13, 1, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 31]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [12, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 11, 31]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [24, 21]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [12, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [12, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 15, 18, 2]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [13, 9, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [27, 26, 3, 16, 23]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [9, 20, 22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [\"NLRP3 inflammasome\", \"PLZF/FAZF/HDAC1 transcriptional repressor complex\", \"pVHL-HIF1α complex\"],\n    \"partners\": [\"GLUT1\", \"NLRP3\", \"JAB1\", \"VHL\", \"AMPK\", \"STAT3\", \"TAK1\", \"CHOP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}